Tongxinluo Regulates Expression of Tight Junction Proteins and Alleviates Endothelial Cell Monolayer Hyperpermeability via ERK-1/2 Signaling Pathway in Oxidized Low-Density Lipoprotein-Induced Human Umbilical Vein Endothelial Cells.
Chengcheng ChangHongli LiuCong WeiLiping ChangJunqing LiangHongying BeiHongrong LiShen LiuYiling WuPublished in: Evidence-based complementary and alternative medicine : eCAM (2017)
Vascular hyperpermeability resulting from distortion of endothelial junctions is associated with a number of cardiovascular diseases. Endothelial tight junction regulates the paracellular permeability of macromolecules, a function of Human Umbilical Vein Endothelial Cells (HUVEC) monolayers that can be regulated by oxidized Low-density Lipoprotein (ox-LDL). However, the understanding of drug regulation of vascular hyperpermeability is so far limited. This study thus aimed to investigate the role of Tongxinluo (TXL) in the maintenance of the vascular endothelial paracellular permeability. Here, changes in permeability were determined by measuring the paracellular flux of FITC-dextran 40000 (FD40), while protein expression and intercellular distribution were examined by western blot and immunofluorescence assay, respectively. We found that TXL alleviated the ox-LDL-induced increase in flux of FD40 and then reduced the hyperpermeability. Moreover, ox-LDL-induced disruptions of ZO-1, occludin, and claudin1 were also restored. This is via the activation of ERK1/2 in the vascular endothelial cells. Our results provide insights into the molecular mechanism by which TXL alleviates ox-LDL-induced hyperpermeability and provide the basis for further investigations of TXL as regulators of vascular barrier function.
Keyphrases
- low density lipoprotein
- endothelial cells
- high glucose
- signaling pathway
- vascular endothelial growth factor
- diabetic rats
- cardiovascular disease
- blood brain barrier
- high throughput
- cell proliferation
- pi k akt
- mouse model
- emergency department
- coronary artery disease
- type diabetes
- metabolic syndrome
- adverse drug
- south africa
- long non coding rna
- transcription factor
- cardiovascular risk factors